Aesthetic Medical International Holdings Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AIH research report →
Price Chart
About the company
Aesthetic Medical International Holdings Group Limited operates as a specialist in diverse cosmetic medical services. The company's comprehensive portfolio features various surgical aesthetic procedures, such as ophthalmic surgery, rhinoplasty, breast enlargement, and liposuction. Additionally, it offers non-surgical aesthetic treatments, which encompass minimally invasive techniques and energy-based therapies like laser, ultrasound, and ultraviolet light applications.
- CEO
- Pengwu Zhou
- IPO
- 2019
- Employees
- 1,286
- HQ
- Shenzhen, CN
Get TickerSpark's AI analysis on AIH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.93M
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.09
- EV/EBITDA
- 3.48
- Div Yield
- 0.00%
- Gross Margin
- 46.24%
- Op Margin
- 0.72%
- Net Margin
- -7.38%
- ROE
- -1054.33%
- ROIC
- 2.14%
Latest fiscal year · YoY change
- Revenue
- $682.59M+1.9%
- Gross Profit
- $322.05M-9.4%
- Op Income
- $-48,812,000
- Net Income
- $-37,432,000+50.8%
- EPS
- $-0.85+69.5%
- OCF Growth
- +198.9%
- FCF Growth
- +124.5%
- 52W High
- $1.43
- 52W Low
- $0.29
- 50D MA
- $0.42
- 200D MA
- $0.59
- Beta
- -0.20
- RSI (14)
- 51
- Avg Volume
- 261.83K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aesthetic Medical International’s Q1 2023 revenue fell amid temporary clinic closures, but cost controls and divestitures helped it return to a small net profit.· May 17, 2023
- Revenue was RMB148.9 million, down 7.3% year over year, mainly because of divestments and a temporary January closure.
- Gross profit was RMB72.6 million, with gross margin at 48.8%, down 6.6 percentage points from last year.
- The company reported a net profit of RMB182,000 versus a RMB2.5 million loss a year ago, while management also cited improved SG&A efficiency.
- Selling expenses and G&A both declined as a percentage of revenue, helped by lower online advertising and asset divestitures.
- Management said it remains optimistic on 2023 as operations normalize, consumers resume spending on self-care, and the company continues portfolio optimization.
For Q1 2023, total revenue was RMB148.9 million, down 7.3% from RMB160.7 million in Q1 2022. Gross profit was RMB72.6 million, down 18.4% year over year, and gross margin fell 6.6 percentage points to 48.8%. The company reported a net profit of RMB182,000 versus a loss of RMB2.5 million in Q1 2022; CFO commentary also cited a loss of RMB12.2 million for the quarter, basic and diluted loss per share of RMB12.04, EBITDA profit of RMB19.9 million, adjusted EBITDA of RMB23.7 million, and adjusted profit after tax of RMB4 million. Looking ahead, management did not provide explicit next-quarter or full-year financial guidance, but said it will continue the current strategy of divesting underperforming assets, reducing lower-price promotions, and focusing on sustainable long-term growth.
Derrick Shi’s commentary focused on portfolio cleanup, operational recovery, and confidence in demand. He said the company divested two underperforming treatment centers, expects a renovation project at Shenzhen Pengcheng Hospital to complete by June, and noted an agreement tied to a $5 million convertible note that should further strengthen the balance sheet. His tone was optimistic, saying consumers may be more willing to spend on self-care and personal appearance as the economy recovers.
Toby Wu framed the quarter as a mix of top-line pressure and cost discipline. He said revenue fell 7.3% year over year due to divestments and a temporary clinic closure, while gross profit was RMB72.6 million and gross margin was 48.8%, down 6.6 percentage points. Selling expenses were RMB42.4 million, or 28.5% of revenue, and G&A was RMB24.7 million, down 21.6% year over year; both benefited from lower online advertising and the divestment of underperforming assets. He also cited average spending per customer rising 1.4% to RMB3,009 from RMB2,967, driven by removing lower-price promotions.
There was no substantive analyst Q&A in the transcript, so no specific investor concerns were addressed live. The closest thing to guidance came in management’s closing remarks, which reiterated the strategy to keep optimizing the asset base, improve service quality, and pursue sustainable long-term growth. Management also pointed to the note conversion/closing as a way to strengthen financial position.
The bull case is that the business showed it can stay profitable even with weaker revenue, thanks to sharper cost control and portfolio pruning. Average spending per customer increased to RMB3,009, and management sounded confident that demand for aesthetic services should improve as consumer finances recover.
The bear case is that revenue and gross profit both declined, and gross margin compressed meaningfully because of temporary clinic closures and prior divestments. The call also showed continued dependence on restructuring actions for profitability, with no explicit revenue or earnings guidance provided for the next quarter or full year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 35.1%
- Shares Outstanding
- 15.93M
- Float Shares
- 5.58M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Idg-Accel China Growth Fund Iii Associates L.P. | 369.87K | ▼ 42.60K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 16, 06 | SCHARLAU CHARLES E | other | 250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AIH coverage
Recent articles, reports, and earnings notes.
No research on AIH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AIH report →Marimaca Copper Announces the Appointment of Kieran Daly to its Board of Directors
globenewswire.com · Aug 8
Marimaca Copper Announces C$68 Million Strategic Investment by Assore International Holdings (AIH) Including Private Placements Totaling C$30.3 Million led by AIH
globenewswire.com · Jul 16
Aesthetic Medical International Holdings Group Ltd. Announces the Commencement of OTCQX Trading
globenewswire.com · Jul 10
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Delisting Decision from the Nasdaq Hearings Panel
globenewswire.com · May 20
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Decision from the Nasdaq Hearings Panel for Conditional Continued Listing
globenewswire.com · Apr 25
Aesthetic Medical International to Announce FY2023 Annual Report on April 25, 2024
globenewswire.com · Apr 18
Why Is Aesthetic Medical (AIH) Stock Up 44% Today?
investorplace.com · Apr 3
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of a Letter of Expected Delisting Determination From Nasdaq Staff and Intention to Request a Hearing before the Nasdaq Hearings Panel
globenewswire.com · Mar 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.